[Wolff-Parkinson-White syndrome. Outcome of patients treated with anti-arrhythmia agents from data of electrophysiological examinations]

Arch Mal Coeur Vaiss. 1988 Feb;81(2):171-5.
[Article in French]

Abstract

Seventy-two consecutive patients with electrocardiographic evidence of Wolff-Parkinson-White syndrome underwent electrophysiological study (EPS). Fifty-five of these patients (76 p. 100) had episodes of tachycardia, 11 experienced palpitations or syncopes and 6 were asymptomatic. The decision to prescribe an antiarrhythmic agent was reached on the basis of the patients' symptoms and EPS data. One patient was treated by surgery before the medical treatment was tried; 17 patients were discharged without treatment, 4 were discharged with an episodic and 50 with a preventive antiarrhythmic treatment. Among these 50 patients, 46 (92 p. 100) could be followed up for a mean period of 45.7 +/- 28 months. One died of lung cancer; 43 presented with spontaneous episodes of tachycardia, 4 were able to discontinue treatment at the end of the follow-up period since they had very few symptoms and 2 were lost sight of. Among the 37 patients under antiarrhythmic treatment followed up, 29 (78 p. 100) are well controlled, while 8 (22 p. 100) still present with episodes of tachycardia. A tachycardia-reducing pacemaker was implanted in 5 of these 8 patients. It therefore appears that 78 p. 100 of patients presenting with spontaneous episodes of tachycardia associated with WPW syndrome can be controlled with an antiarrhythmic treatment. This result was obtained after trying at least two types of antiarrhythmic agents in 86 p. 100 of the cases.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Anti-Arrhythmia Agents / therapeutic use*
  • Electrophysiology
  • Female
  • Follow-Up Studies
  • Heart Conduction System
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Tachycardia / drug therapy*
  • Tachycardia / etiology
  • Wolff-Parkinson-White Syndrome / complications
  • Wolff-Parkinson-White Syndrome / drug therapy*
  • Wolff-Parkinson-White Syndrome / physiopathology

Substances

  • Anti-Arrhythmia Agents